Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564087 | 0.84 | LMNA (0.53) | ALDH1A1LMNASMN1; SMN2NPSR1HTT | |
| SCHEMBL1179641 | 0.83 | GAA (0.46) | KMT2AALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1178745 | 0.80 | ALDH1A1 (0.52) | KMT2AALDH1A1MAPTNPSR1HTT | |
| SCHEMBL11297030 | 0.79 | KMT2A (0.54) | KMT2AALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL3338421 | 0.77 | HSD11B1 (0.36) | HSD11B1 | |
| SCHEMBL14399470 | 0.72 | ALDH1A1 (0.51) | KMT2AALDH1A1PSIP1LMNAKDM4E | |
| SCHEMBL12580250 | 0.72 | ALDH1A1 (0.51) | KMT2AALDH1A1PSIP1LMNAKDM4E | |
| SCHEMBL1178964 | 0.72 | CA2 (0.47) | ALDH1A1LMNA | |
| SCHEMBL31530734 | 0.70 | TDP1 (0.45) | KMT2AALDH1A1PSIP1LMNAKDM4E | |
| SCHEMBL5605632 | 0.69 | ALDH1A1 (0.42) | KMT2AALDH1A1PSIP1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1761485-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
| US-6596863-B2 | Matrix metalloproteinase inhibitor is useful as an anticancer agent, angiogenesis inhibitor, a tumor cell infiltration inhibitor or a tumor metastasis inhibitor; inflammatory diseases, osteoarthritis, rheumatoid arthritis | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20020198184-A1 | Medical composition containing nitroetheneamine derivative or salt thereof as active constituent | ISHIHARA SANGYO KAISHA LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6451792-B1 | MATRIX METALLOPROTEASE INHIBITORS | ISHIHARA SANGYO KAISHA LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| EP-1116486-A1 | MEDICAL COMPOSITION CONTAINING NITROETHENEAMINE DERIVATIVE OR SALT THEREOF AS ACTIVE CONSTITUENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2001-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | KMT2A 4394/4885ALDH1A1 4189/4885PSIP1 1397/4885 |
| US-20020198184-A1 | Medical composition containing nitroetheneamine derivative or salt thereof as active constituent | NR3C2, NR3C1, CNR1 | KMT2A 2432/4885ALDH1A1 1194/4885PSIP1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.